Today's Date: December 11, 2023
CareerPhysician Welcomes Dr. Bruce Rubin to the Child Health Advisory Council   •   Hawaiian Electric Company Announces Ameresco Award for Two Clean Energy Projects Totaling 111 MW   •   Trane Technologies Named to S&P Dow Jones Sustainability World and North American Indices   •   Cedar Fair Announces Strategic Changes to Its Corporate Leadership Team   •   Paralyzed Veterans of America issues statement in response to accessible drop-off zones coming to Capitol Hill   •   Publix Register Campaign Supports American Red Cross Disaster Relief Efforts in Tennessee   •   Kinetik Announces Secondary Offering of Common Stock   •   GROUNDBREAKING PARTNERSHIP UNVEILED: CANADA'S LEADING PAEDIATRIC HOSPITALS AND THE AZRIELI FOUNDATION JOIN FORCES TO TRANSFORM C   •   McCormick & Company's 2050 Net-Zero Target Validated by Science Based Targets Initiative   •   Darling Ingredients Again Named to Newsweek's America's Most Responsible Companies List   •   Whirlpool Corporation Named to 2023 Dow Jones Sustainability World Index for Second Consecutive Year   •   UrbanGeekz Unveils Inaugural UrbanGeekz 50 to Showcase Gamechangers in Tech, Innovation and Entrepreneurship   •   Minister O'Regan receives Task Force report on Employment Equity Act modernization   •   Independent study finds that Amplify Science K–5 fulfills mission of the Next Generation Science Standards (NGSS) and supp   •   Blue Bird Reports Fiscal 2023 Fourth Quarter and Full Year Record Results; Beats 2023 Guidance and Raises 2024 Guidance   •   American Water Charitable Foundation Invests in California’s Future with Workforce Readiness and STEM Education Grants   •   Supporting Safer Sleep: Sleepopolis Donates $30,000 to Children in Need Across the Nation   •   Textron Aviation announces new SustainableAdvantage carbon offset program for Cessna, Beechcraft and Hawker owners   •   University of Phoenix College of Doctoral Studies Expanded Pilot for Mentoring Enhances Holistic Support System for Working Adul   •   Northeast Delta HSA catalyzes Veteran's Boxing Wellness Initiative Through Partnership With Rodney J. Hobbs VFW Post 1809, BoneK
Bookmark and Share

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

TAMPA, Fla. , September 29 /Businesswire/ - Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This milestone follows rigorous testing and validation of Oragenics’ biological samples, which are poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts.

Under this agreement, Oragenics has received a cash payment of $50,000 alongside an enticing opportunity to acquire one million shares of Lantern Bioworks’ equity. Additionally, Lantern Bioworks has committed to pay Oragenics a ten percent (10%) royalty on the net income generated from any products stemming from the transferred assets. The royalty payments span a ten (10)-year term.

Kim Murphy, the President and Chief Executive Officer of Oragenics, expressed enthusiasm, stating, “We are elated to witness these assets continue their journey, contributing to the scientific legacy that Oragenics has cultivated over many years. Dental caries remains a pervasive global oral health challenge, and replacement-therapy approach holds immense promise in offering enduring protection against this disease.”

Of importance to note, these samples remain distinct from Oragenics’ current or ongoing research endeavors, specifically in the realms of Lantibiotics or SARS-CoV-2 vaccine candidates. Instead, they originated from a prior research and development project that Oragenics had temporarily suspended, awaiting an opportune application.

Lantern Bioworks has demonstrated a keen interest in harnessing the potential of these samples to fortify their ongoing product development initiatives.

Crucially, this agreement does not entail the transfer of intellectual property ownership from Oragenics to Lantern Bioworks.

About Oragenics

Oragenics, Inc. is a development-stage company focused on nasal delivery of pharmaceutical medications including in neurology and fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC) with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its Lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information, please visit

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: Lantern Bioworks ability to successfully develop and commercialize the transferred assets; Lantern Bioworks ability to generate net income from any products stemming from the transferred assets; uncertainties related to the value of Lantern Bioworks should Oragenics elect to purchase equity of Lantern Bioworks; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

STORY TAGS: Contract/Agreement, Merger/Acquisition, Product/Service, Florida, United States, North America, Canada, Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Dental,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News